

ASX Announcement**24 November 2025****Change of Auditor**

In compliance with ASX Listing Rule 3.16.3, **Tissue Repair Limited (ASX:TRP)** (Tissue Repair or the Company) advises that Stantons International Audit and Consulting Pty Ltd have been appointed as auditor of the Company.

The appointment was made by the Company's members by ordinary resolution at the Annual General Meeting held on 24 November 2025. The change follows the resignation of the Company's previous auditor, Pitcher Partners Sydney in accordance with Section 329(5) of the Corporations Act and approval from ASIC.

This announcement has been approved by the Company Secretary of Tissue Repair for release to the ASX.

--END--

About Tissue Repair

Tissue Repair Limited (ASX: TRP) is a Phase 3 biotechnology company developing second-generation wound healing agents. The company is advancing its lead drug candidate *TR987*[®] for chronic wounds and commercialising *TR Pro+*[®], a topical treatment designed to accelerate healing and improve skin quality following cosmetic or medical procedures. Its proprietary *Glucoprime*[®] API underpins a growing pipeline of therapeutic solutions.